First Turn Management »

Enliven Therapeutics shares owned by First Turn Management

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by First Turn Management from 13F filings

Historical chart of First Turn Management investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by First Turn Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by First Turn Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $14M 535k 25.54

More positions owned by First Turn Management

Nuvalent Inc-a (NUVL)
Argenx Se Sponsored Adr (ARGX)
Insmed Com Par $.01 (INSM)
Mirum Pharmaceuticals (MIRM)
Vaxcyte (PCVX)
Axsome Therapeutics (AXSM)
Syndax Pharmaceuticals (SNDX)
Ascendis Pharma A/s Sponsored Adr (ASND)
Natera (NTRA)
Intra Cellular Therapies (ITCI)
Crinetics Pharmaceuticals In (CRNX)
Transmedics Group (TMDX)
Arcellx Common Stock (ACLX)
Blueprint Medicines (BPMC)
Verona Pharma Sponsored Ads (VRNA)

View all positions for First Turn Management

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
VR Adviser
Fairmount Funds Management
BlackRock
Vanguard Group
5AM Venture Management
Citadel Advisors
RA Capital Management
Henderson Group
Pictet Asset Management Holding SA
Woodline Partners
Adage Capital Partners GP
Geode Capital Management

View all funds holding Enliven Therapeutics